Active, not recruitingPhase 2NCT03158064

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Studying Tumor of testis and paratestis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Samuel Funt, MD
Memorial Sloan Kettering Cancer Center
Intervention
Durvalumab(drug)
Enrollment
30 enrolled
Eligibility
18 years · All sexes
Timeline
20172026

Study locations (7)

Collaborators

AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03158064 on ClinicalTrials.gov

Other trials for Tumor of testis and paratestis

Additional recruiting or active studies for the same condition.

See all trials for Tumor of testis and paratestis

← Back to all trials